Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
about
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerAntibody-drug conjugates as novel anti-cancer chemotherapeuticsHigh-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Combinatorial biosynthesis--potential and problems.Perspectives: Other ErbB2-Targeted Therapies.A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Antibody-DM1 conjugates as cancer therapeutics.Eradication of large colon tumor xenografts by targeted delivery of maytansinoidsInitial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Computational Construction of Antibody-Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable LinkerImmunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancerA Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor CellsPhase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsAntibody-drug conjugates: Intellectual property considerations.Methods for site-specific drug conjugation to antibodies.Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Advances in the treatment of hematologic malignancies using immunoconjugatesLorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.Analytical methods for physicochemical characterization of antibody drug conjugatesDrug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.Novel Molecular Multilevel Targeted Antitumor AgentsDecoupling stability and release in disulfide bonds with antibody-small molecule conjugates.Emerging and investigational therapies for neuroblastoma.Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody.
P2860
Q24632855-B549EAA4-A471-436E-84A6-8F69B15EB6DEQ26800175-2A876D37-ED81-43C3-ADDD-9EF0ECFA9D76Q30524836-9A7D282A-CE17-4278-AC2E-7C3557323223Q33231690-884DE701-707B-4FDE-AEFC-DFF0C6EC1C46Q34096252-9DAFA76D-C8A4-4883-AB2D-8C8C041E1D28Q34099745-A6E51FA2-E255-442C-AD28-99FFABFBFA91Q34162875-C43A7F0C-407C-424C-8441-A23B09F2B0D0Q34177359-DD4CD0B5-54A2-45B5-9F65-1C20234455AFQ34389426-A0F4457D-5BB2-4F9F-95F6-554DD2727244Q34660299-B5BE1AB3-9402-4300-8EDB-FA763A60284BQ34663010-8A6C3591-6A20-4EF2-B252-437E5085C5B7Q35459059-8F37F891-5FA5-459F-BE4B-EE411A4C93B4Q36220464-1AF808E6-A0FB-483B-BB94-F2F9FDA245C2Q36269852-BBC1F0C2-C7C0-444B-BE15-6657833D14EFQ36879421-D9A07B55-C560-4067-83B1-732C2C81DBB5Q37138213-E8E1B20C-C122-4CCF-91FD-202281872D42Q37593707-2F05FE70-C50C-4397-B3E1-4902BBB77882Q37600390-8E08B74F-BB71-4CA3-A0AA-385B8BBD7B03Q37601692-D41D7359-D7CF-4C0E-8C46-BC747F08FBB1Q37628646-9EB1609F-25F8-4915-A552-E46B857360D8Q37680178-C47BDA7C-18F3-4039-9FA4-DA7885A24B39Q37697843-DDA7E38F-9C0C-485A-9D3C-18362DC97F9CQ37698957-E49E706B-ECD5-42D9-96D4-968B42C18515Q37858385-8F592686-5D36-44D5-9DBC-4E371F3F1F80Q38084826-07F6A26B-8723-46E2-AD21-2440CE5529FEQ39645683-574D3692-A56A-4E2D-9324-8C93061E2A98Q41239615-BEE6ADA6-E22D-4059-B7C8-54FA0205E483Q41429679-5366A5D0-2DE1-4883-B4E3-1C8E36E095D3Q42314398-1860DCB7-6B84-46C4-B6FE-E88B54C0ABE7Q50073387-2C016893-EEAF-4AD0-9D49-DA38FD082711Q55257821-BA2538E6-6571-4554-BDDC-E93D95B9DC8B
P2860
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@ast
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@en
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@nl
type
label
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@ast
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@en
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@nl
prefLabel
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@ast
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@en
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@nl
P2093
P1433
P1476
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
@en
P2093
Blättler WA
Goldmacher VS
Martell BA
McKenzie SJ
P304
P407
P577
1992-01-01T00:00:00Z